Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

Momenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on Autoimmunity

Anthony M. Manning, PHD.

SLIDE PRESENTATION May 19, 2018

Excerpts:

Page 16 - Potential Indications for M281: THREE TIERS [WOW!!]

1. Receptor Block + IgG Reduction

Alloimmune syndromes; transfusion reactions, transplant rejection, fetal maternal diseases

2. IgG Reduction

• Myasthenia gravis
• Pemphigus
• ITP
• Warm autoimmune Hemolytic anemia
• Autoimmune neutropenia
• Antibody-mediated graft rejection
• Guillain-Barre Syndrome • Autoimmune encephalitis • ANCA vasculitis

3. IgG Reduction and Other/Unknown Mechanisms (*)

• Multiple Sclerosis
• Neuromyelitis Optica
• Chronic Inflammatory demyelinating Polyneuropathy
• Dermatomyositis
• Lupus and Lupus nephritis • Sjogren’s Syndrome
• Goodpasture Syndrome

Read more:
http://ir.momentapharma.com/static-files/690fd799-dd04-4ae5-b41a-9f9252bc18e8